Ask AI

Personalizing Bispecific Antibody Therapy for Your Patients With Multiple Myeloma: Clinical Fundamentals, Current Evidence, and Expert Strategies for Community HCPs

Text Module
Text Module Start Activity
This activity is available for 0.50 CME/CE credit(s).

Released: August 18, 2026

Expiration: February 17, 2027

See Activity Collection

In this text-based module, a clinical hematologist reviews the rapidly evolving role of bispecific antibodies (BsAbs) in multiple myeloma, with a focus on BCMA- and GPRC5D-directed therapies, their mechanisms of action, pivotal and emerging clinical trial data, and characteristic safety considerations such as cytokine release syndrome, neurotoxicity, infection risk, and target-specific adverse events. The faculty also examines the use of these agents in heavily pretreated disease and their movement into earlier treatment settings and combination regimens, while also addressing sequencing after prior BCMA-directed therapy, potential mechanisms of treatment failure, and the relative clinical and logistical considerations of BsAbs vs CAR T-cell therapy. By integrating efficacy, durability, safety, sequencing, and real-world feasibility, this module will help you evaluate where BsAbs may fit within individualized treatment strategies for patients with relapsed/refractory multiple myeloma.

Clinical Pearls of BsAbs in MM

Pre Assessment

Assess your current knowledge and clinical approach before beginning your text module.
1.

How many people with MM do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Assume that a trial is enrolling participants at your institution. This trial has 3 arms and is evaluating combinations with bispecific antibodies (BsAbs) against the standard of care in patients with relapsed/refractor (R/R) multiple myeloma (MM). All of the following factors are barriers that could affect a patient’s eligibility to receive treatment with a BsAb EXCEPT which one? 

4.

A 75-year-old woman was diagnosed with MM in 2018. She received bortezomib, lenalidomide and dexamethasone followed by autologous stem cell transplant and lenalidomide maintenance therapy. She achieved a complete response (CR) that was maintained for 8 years and now has disease recurrence on lenalidomide. She was referred for consideration of CAR T-cell therapy and has declined this treatment.

Which of the following approved second-line treatment options would you recommend for this patient?